ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM)

Similar Items

• ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS
  od: Bota, Daniela A, i dr.
  Izdano: (2018)
• ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)
  od: Bota, Daniela, i dr.
  Izdano: (2017)
• NIMG-46. LONGITUDINAL RESTING-STATE FUNCTIONAL CONNECTIVITY CONFIRMS MARIZOMIB (MRZ) CROSSES THE BLOOD BRAIN BARRIER (BBB) AND CORRELATES WITH HALLUCINATION SEVERITY IN RECURRENT GBM PATIENTS
  od: Keator, David B, i dr.
  Izdano: (2018)
• ACTR-38. A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
  od: Saran, Frank, i dr.
  Izdano: (2018)
• OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth()()
  od: Towner, Rheal A., i dr.
  Izdano: (2018)